MAINZ, Germany, August 28, 2026, 10:06 (EDT) – Shares of BioNTech (BNTX.O) fell 6.6% after the board decided to end a trial testing its experimental vaccine for colorectal cancer.
- Shares of BioNTech ADSs dropped 6.6% to $104.09 at 10:05 EDT.
- An independent board has advised discontinuing the Phase 2 study for colorectal cancer.
- Research and development expenses for the quarter amounted to 5.2 times the revenue reported in the second quarter.
BioNTech SE (NASDAQ: BNTX) American depositary shares dropped 6.6% on Friday following the company’s decision to halt a Phase 2 study of autogene cevumeran. The individualized mRNA immunotherapy was under evaluation post-surgery for patients with high-risk colorectal cancer.
Shares were last seen at $104.09 as of 10:05 EDT. The decline wiped approximately $1.8 billion off BioNTech’s June market capitalization market data.
An independent data safety monitoring board advised halting treatment and ending the trial. The board noted a numerical difference in overall survival across the study groups.
The board further determined that extending the study would probably not affect the efficacy results. BioNTech collaborated on the candidate with Genentech, a division of Roche Reuters.
| Investor measure | Latest figure | Why it matters |
|---|---|---|
| BNTX price | $104.09, down 6.6% | Roughly $1.8 billion in market value lost |
| Trial | Phase 2, NCT05968326 | Colorectal-cancer monotherapy program halted |
| Q2 revenue | €105.6 million | Dropped 60% on an annual basis |
| Q2 R&D expense | €551.0 million | R&D spending is 5.2 times higher than revenue for the quarter |
| Q2 net loss | €820.8 million | Net loss more than doubled from the prior year |
| Cash and securities | €16.63 billion | Sustains the rest of the oncology pipeline |
The study included patients who had previously undergone surgery for stage II high-risk or stage III tumors. Every participant continued to test positive for circulating tumor DNA, indicating the presence of residual disease risk.
The move eliminates one path for development but does not determine the future of BioNTech’s remaining oncology projects or its additional research into personalized immunotherapy.
The main financial impact concerns pipeline valuation. BioNTech continues to invest significantly in advancing its cancer portfolio toward commercialisation.
R&D spending in the second quarter totaled €551 million. Revenue stood at €105.6 million, and net loss increased to €820.8 million BioNTech results.
The balance sheet allows flexibility to reallocate capital. As of June 30, BioNTech reported €16.63 billion in cash and securities.
The company projects adjusted R&D expenses will reach between €2.0 billion and €2.3 billion this year. Earlier this month, management also reduced its revenue forecast for 2026 to a range of €1.6 billion–€1.9 billion.
Analysts hold a positive view ahead of factoring in Friday’s developments. Consensus among twenty analysts is Buy, with an average price target of $121.51 analyst snapshot.
Risks: Additional analysis may alter the understanding of the survival imbalance. Positive results from other oncology studies might recover value, whereas more halted trials could hasten expenditure and narrow the pipeline.
![Asia Stock Market Today 28/08/2026 [UPDATE: 22:56 SGT] [KASE Global Keeps Asia Trading as Warsh Revives Hike Risk]](https://ts2.tech/wp-content/uploads/2026/08/Asia-market-dashboard-2026-08-28-2255-480x384.jpg "Asia Stock Market Today 28/08/2026 [UPDATE: 22:56 SGT] [KASE Global Keeps Asia Trading as Warsh Revives Hike Risk]")
